Table 6.

Pharmacokinetic summary of decitabine following 3-day treatment and 5-day treatment (pharmacokinetic analysis set)

Treatment	C max (ng/mL)	T max (h)	AUClast (ng h/mL)	AUC0–∞ (ng h/mL)	T 1/2 (h)
3-day treatmenta (n = 6)
Mean	54.44	2.43	117.84	118.93	0.58
SD	20.07	0.79	50.37	50.55	0.22
CV%	36.87	32.51	42.74	42.50	38.42
5-day treatmentb (n = 18)
Mean	222.35	0.88	179.23	180.43	0.63
SD	53.74	0.24	43.84	43.78	0.18
CV%	24.17	27.67	24.46	24.26	29.13

Pharmacokinetic analysis set included all patients who were randomized and participated in the pharmacokinetic assessments

AUC Area under curve, C _max Observed maximum plasma concentration, CV Coefficient of variation, T _1/2 Terminal half-life, T _max Time when C_max was observed

^a15 mg/m² administered over 3 h as an intravenous infusion every 8 h for 3 consecutive days

^b20 mg/m² administered over 1 h as an intravenous infusion once- daily for 5 consecutive days